Vertex Pharmaceuticals said Wednesday that it has shelved an experimental drug to treat a rare, inherited lung disease due to liver toxicity reported in a mid-stage clinical trial.
The discontinuation of the drug, called VX-814, is a rare clinical development setback for Vertex, which has strung together a long list of successful treatments for cystic fibrosis.
About the Author Reprints
